Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure

Journal of Bone and Mineral Research

Volumn 27, Issue 8, 2012, Pages 1811-1820

  Gafni, Rachel I ^a   Brahim, Jaime S ^b   Andreopoulou, Panagiota ^c   Bhattacharyya, Nisan ^a   Kelly, Marilyn H ^a   Brillante, Beth A ^a   Reynolds, James C ^d   Zhou, Hua ^e   Dempster, David W ^e   Collins, Michael T ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e HELEN HAYES HOSPITAL   (United States)

Author keywords

HISTOMORPHOMETRY; HYPOPARATHYROIDISM; PTH

Indexed keywords

CALCIUM; MAGNESIUM; PARATHYROID HORMONE[1-34]; PHOSPHORUS;

ADULT; ARTICLE; BONE DENSITY; BONE MARROW BIOPSY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CANCELLOUS BONE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; HYPOPARATHYROIDISM; MAGNESIUM BLOOD LEVEL; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOID; PHOSPHATE BLOOD LEVEL; POROSITY; SPINE; TRABECULAR BONE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE REMODELING; DENSITOMETRY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPARATHYROIDISM; ILIUM; MALE; MIDDLE AGED; OSTEOGENESIS; PARATHYROID HORMONE; POROSITY; YOUNG ADULT;

EID: 84864137041     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1627     Document Type: Article

References (31)

1. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP., Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008; 23 (12): 2018-24.
2. Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P., Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 1996; 18 (2): 103-8.
3. Winer KK, Yanovski JA, Cutler GB Jr., Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996; 276 (8): 631-6.
4. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr., Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003; 88 (9): 4214-20.
5. Rubin MR, Dempster DW, Sliney J Jr, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP., PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011; 26 (11): 2727-36.
6. Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP., Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010; 21 (11): 1927-34.
7. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L., The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26 (10): 2358-70.
8. Sikjaer T, Rejnmark L, Thomsen JS, Tietze A, Bruel A, Andersen G, Mosekilde L., Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study. J Bone Miner Res. 2012; 27 (4): 781-8.
9. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA., The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab. 2007; 92 (6): 2087-99.
10. Dempster DW, Shane ES., Bone quantification and dynamics of bone turnover by histomorphometric analysis. In:, Becker KL, editor. Principles and Practice of Endocrinology and Metabolism. 2nd ed. Philadelphia: JB Lippincott Co.; 1995. p 491-8.
11. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
12. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S., Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res. 1988; 3 (2): 133-44.
13. Clarke BL, Ebeling PR, Jones JD, Wahner HW, O'Fallon WM, Riggs BL, Fitzpatrick LA., Changes in quantitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab. 1996; 81 (6): 2264-70.
14. Parisien M, Cosman F, Morgan D, Schnitzer M, Liang X, Nieves J, Forese L, Luckey M, Meier D, Shen V, Lindsay R, Dempster DW., Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res. 1997; 12 (6): 948-57.
15. Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM., Normative data for iliac bone histomorphometry in growing children. Bone. 2000; 26 (2): 103-9.
16. Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK., PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res. 2009; 24 (5): 964-73.
17. Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J., Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone. 2009; 44 (1): 113-9.
18. Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S., Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months. Calcif Tissue Int. 2011; 89 (2): 130-9.
19. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434-41.
20. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R., Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16 (10): 1846-53.
21. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R., Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003; 88 (3): 1150-6.
22. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS., Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009; 94 (8): 2915-21.
23. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM., Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA. 1998; 280 (12): 1067-73.
24. Abugassa S, Nordenstrom J, Eriksson S, Sjoden G., Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 1993; 76 (6): 1617-21.
25. Winer KK, Yanovski JA, Sarani B, Cutler GB Jr., A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998; 83 (10): 3480-6.
26. Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr., Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008; 93 (9): 3389-95.
27. Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler GB Jr., Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2011; 97 (2): 391-9.
28. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY., Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007; 41 (3): 321-30.
29. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ., Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005; 36 (6): 948-58.
30. Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA., A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res. 1999; 14 (10): 1672-9.
31. Wang Q, Wang XF, Iuliano-Burns S, Ghasem-Zadeh A, Zebaze R, Seeman E., Rapid growth produces transient cortical weakness: a risk factor for metaphyseal fractures during puberty. J Bone Miner Res. 2010; 25 (7): 1521-6.